Anti-VEGF therapy led to significant changes in both BCVA and CST at 12 months (P < 0.001). Younger patients, shorter duration of diabetes and NPDR were associated with improved results. The visual and anatomic improvements were sustained over the full duration of the study.
Priya et al. (Thu,) studied this question.